Semiparametric regression models on the cumulative incidence function for interval-censored competing risks data as described in Bakoyannis, Yu, & Yiannoutsos (2017) /doi{10.1002/sim.7350} and the models with missing event types as described in Park, Bakoyannis, Zhang, & Yiannoutsos (2021) \doi{10.1093/biostatistics/kxaa052}. The proportional subdistribution hazards model (Fine-Gray model), the proportional odds model, and other models that belong to the class of semiparametric generalized odds rate transformation models.

Provides a systematic framework for
 integrating multiple modalities of assays profiled on the same set of
 samples. The goal is to identify genes that are altered in cancer
 either marginally or consistently across different assays. The
 heterogeneity among different platforms and different samples are
 automatically adjusted so that the overall alteration magnitude can
 be accurately inferred. See Tong and Coombes (2012) 
 <doi:10.1093/bioinformatics/bts561>.

Generates a 'Graphviz' graph of the most significant 3-way 
    interaction gains (i.e. conditional information gains) based on a provided 
    discrete data frame. Various output formats are supported ('Graphviz', SVG, 
    PNG, PDF, PS). For references, see the webpage of Aleks Jakulin 
    <http://stat.columbia.edu/~jakulin/Int/>.

Offers modeling the association between gene-expression and bioassay data, taking care of the effect due to a fingerprint feature and helps with several plots to better understand the analysis.

The integrity package implements the IPD Integrity Tool, a
    structured and transparent framework for evaluating the integrity of
    individual participant data (IPD) from randomised trials (see Hunter et
    al. (2024) <doi:10.1002/jrsm.1738> and <doi:10.32614/RJ-2017-008>). It
    supports users to identify potential issues, such as unusual data
    patterns, implausible values, lack of expected correlations, date
    violations, and inconsistencies. The package provides reproducible
    workflows for screening, documenting and summarising integrity concerns,
    and may be applied by evidence synthesists, editors, and others to
    determine whether a randomised trial may be considered sufficiently
    trustworthy to contribute to the evidence base that informs policy and
    practice.